You are here:

telaprevir (Incivo) Exp

Advice

following a full submission:

telaprevir (Incivo®) is accepted for use within NHS Scotland.

Indication under review: In combination with peginterferon alfa and ribavirin, is indicated for the treatment of genotype 1 chronic hepatitis C in adult patients with compensated liver disease (including cirrhosis) who have previously been treated with interferon alfa (pegylated or non-pegylated) alone or in combination with ribavirin, including relapsers, partial responders and null responders. 

In the pivotal phase III randomised study, the addition of telaprevir to current standard therapy in patients with genotype 1 chronic hepatitis C virus, who had failed previous therapy, significantly increased the proportion of patients who achieved a sustained virologic response.

Drug Details

Drug Name: telaprevir (Incivo) Exp
SMC Drug ID: 742/11
Manufacturer: Janssen-Cilag Ltd
Indication: In combination with peginterferon alfa and ribavirin (PR), for the treatment of genotype 1 chronic hepatitis C in adult patients with compensated liver disease (including cirrhosis): who have previously been treated with interferon alfa (pegylated or non pegylated) alone or in combination with ribavirin, including relapsers, partial responders and null responders
BNF Category:
Submission Type: Full submission
Status: Accepted
Date Advice Published: 12 December 2011

Back